230 results on '"Bertucci, Francois"'
Search Results
2. An integrated tumor, immune and microbiome atlas of colon cancer.
3. Discontinuation versus continuation of imatinib in patients with advanced gastrointestinal stromal tumours (BFR14): exploratory long-term follow-up of an open-label, multicentre, randomised, phase 3 trial
4. Impact of age on safety of Busulfan-Melphalan followed by autologous hematopoietic stem-cell transplantation versus standard chemotherapy in the patients of the EURO-E.W.I.N.G. 99 and Ewing 2008 clinical trials
5. Long term survival in adult osteosarcoma patients treated with a two-drug regimen: Final results of the OSAD93 phase II study of the FSG-GETO
6. Synthèse des profils de toxicité des anticorps drogue-conjugués dans le cancer du sein
7. XIAP overexpressing inflammatory breast cancer patients have high infiltration of immunosuppressive subsets and increased TNFR1 signaling targetable with Birinapant
8. Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial
9. Pembrolizumab in patients with rare and ultra-rare sarcomas (AcSé Pembrolizumab): analysis of a subgroup from a non-randomised, open-label, phase 2, basket trial
10. Mechanistic modeling of metastatic relapse in early breast cancer to investigate the biological impact of prognostic biomarkers
11. Axin1 Protects Colon Carcinogenesis by an Immune-Mediated Effect
12. Pathological complete response rate and disease-free survival after neoadjuvant chemotherapy in patients with HER2-low and HER2-0 breast cancers
13. Molecular profiling of non-small-cell lung cancer patients with or without brain metastases included in the randomized SAFIR02-LUNG trial and association with intracranial outcome
14. Évolution et facteurs associés à la publication des travaux de thèse d’exercice par les internes d’oncologie médicale en France
15. A Multicenter Phase II Study of Pazopanib in Patients with Unresectable Dermatofibrosarcoma Protuberans
16. Santé numérique et « cancer hors les murs », Big Data et intelligence artificielle
17. BMI1 nuclear location is critical for RAD51-dependent response to replication stress and drives chemoresistance in breast cancer stem cells
18. Pazopanib or methotrexate–vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study
19. Localized Myxofibrosarcomas: Roles of Surgical Margins and Adjuvant Radiation Therapy
20. Efficacy and safety of regorafenib compared to placebo and to post-cross-over regorafenib in advanced non-adipocytic soft tissue sarcoma
21. Molecular classification as prognostic factor and guide for treatment decision of pancreatic cancer
22. PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer
23. Surgical versus non-surgical approach in primary desmoid-type fibromatosis patients: A nationwide prospective cohort from the French Sarcoma Group
24. Advanced chordoma treated by first-line molecular targeted therapies: Outcomes and prognostic factors. A retrospective study of the French Sarcoma Group (GSF/GETO) and the Association des Neuro-Oncologues d'Expression Française (ANOCEF)
25. Characterization and Targeting of Platelet-Derived Growth Factor Receptor alpha (PDGFRA) in Inflammatory Breast Cancer (IBC)
26. Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial
27. Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial
28. Bevacizumab plus neoadjuvant chemotherapy in patients with HER2-negative inflammatory breast cancer (BEVERLY-1): a multicentre, single-arm, phase 2 study
29. Cyclin A2 maintains colon homeostasis and is a prognostic factor in colorectal cancer
30. A genome‐wide RNAi screen reveals essential therapeutic targets of breast cancer stem cells
31. Supplementary Table 1 from Contrasted Outcomes to Gefitinib on Tumoral IGF1R Expression in Head and Neck Cancer Patients Receiving Postoperative Chemoradiation (GORTEC Trial 2004-02)
32. Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trial
33. Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): a randomised phase 2 trial
34. Angiogenesis and Lymphangiogenesis in IBC: Insights from a Genome-Wide Gene Expression Profiling Study
35. Microarray Analysis Identifies an Expression Signature for Inflammatory Breast Cancer
36. Patterns of care and outcome of CIC ‐rearranged sarcoma patients: A nationwide study of the French sarcoma group
37. EGFR is a master switch between immunosuppressive and immunoactive tumor microenvironment in inflammatory breast cancer
38. The coenzyme A precursor pantethine restrains sarcoma growth through promotion of type 1 immunity
39. EndoPredict predicts for the response to neoadjuvant chemotherapy in ER-positive, HER2-negative breast cancer
40. A Lesson in Transcriptional Plasticity: Classical Identity Is Silenced, but Not Lost, in Pancreatic Ductal Adenocarcinoma Cell Lines
41. Genomic profiling of inflammatory breast cancer: A review
42. Personalized medicine: Present and future of breast cancer management
43. Timing evolution of lobular breast cancer through phylogenetic analysis
44. Patterns of care and outcome of CIC‐rearranged sarcoma patients: A nationwide study of the French sarcoma group.
45. Simvastatin prevents triple-negative breast cancer metastasis in pre-clinical models through regulation of FOXO3a
46. The immune micro-environment of inflammatory breast cancer is characterized by an influx of CD163+ tumor-associated macrophages.
47. Potential clinical activity of pembrolizumab monotherapy in ovarian sex cords, rare epithelial carcinoma, and other rare ovarian tumor histotypes: The French AcSé pembrolizumab study from Unicancer.
48. PEC-PRO: A new prognostic score from a series of 93 patients with localized perivascular epithelioid cell neoplasms (PEComas) treated with curative intent.
49. Activity of regorafenib in patients with non-adipocytic soft tissue sarcoma (NASTS): Evaluation of heterogeneity of treatment effect on the updated analysis of pooled cohorts.
50. CD47–signal regulatory protein-α (SIRPα) interactions form a barrier for antibody-mediated tumor cell destruction
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.